What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 921946

Cover Image

PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 921946

Conjunctivitis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

PAGES: 112 Pages
DELIVERY TIME: 2-3 business days
PDF & Excel (Single User License)
USD 4750
PDF & Excel (Team License: Up to 7 Users)
USD 5250
PDF & Excel (Site License)
USD 6500
PDF & Excel (Corporate License)
USD 8750

Add to Cart

The market studied is expected to grow in the forecast period due to the high number of people suffering from allergic conjunctivitis and the easier availability of the treatment across the globe.

The National Institute of Health has stated in its 2017 report that the prevalence of conjunctivitis is around 6-30% in the general population and up to 30% in the children across the globe. As the disease is very common, treatment for the same is easily available. Most of the time, the disease is self diagnosable and there is the least need of undergoing any diagnostic test for this disease.

Countries like India are also having a high prevalence of conjunctivitis. As per the article published by a journal named Clinical Epidemiology and Global Health, it was found that during the year 2019, the prevalence of allergic conjunctivitis was around 12.22% and the number of men suffering from this disease is higher than that of females in India. The epidemiology of the disease is similar in other Asian countries such as China.

Hence, owing to the high prevalence of the disease, the market studied is expected to have a steady growth over the forecast period.

Key Market Trends

Allergic Conjunctivitis is Expected to Witness a Steady Growth

The allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. The people having allergies are more likely to develop allergic conjunctivitis. As stated by the Asthma and Allergy Foundation of America, approximately 30% of the adults and 40% of the children suffer from allergies in the United States. The diagnosis of the disease is usually done by self. However, if someone is unable to identify the disease, there are certain tests that the doctor performs to understand the disease and its cause. Some of the tests include allergy skin tests, a blood test to see if the patient's body is producing proteins, or antibodies, to protect itself against specific allergens like mold or dust.

Treatment for acute conjunctivitis includes oral or over the counter (OTC) drugs that reduce the release of histamine. Also, anti-inflammatory or anti-inflammation eye drops are available in the market easily which are found to provide relief in acute conjunctivitis. Hence, this segment will witness steady growth during the forecast period.

United States Dominate the Market

It has been stated by the National Institue of Health that conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.

Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share in the near future.

Competitive Landscape

The market for conjunctivitis treatment includes international as well as local companies. The disease is self diagnosable and does not always need hospitalization. Therefore, people rely on home remedies or over the counter drugs for treatment. The local companies across various countries are doing a good business in this market as the cost of the drug is less and the preference of people about OTC is increasing.

For instance, Lupin has launched generic conjunctivitis treatment drug, Moxifloxacin Hydrochloride Ophthalmic solution in the United States.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 67343



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of People Suffering From Conjunctivitis
    • 4.2.2 Easy Availability of the Treatment
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatments Such as Home Remedies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Disease Type
    • 5.1.1 Allergic Conjunctivitis
    • 5.1.2 Bacterial Conjunctivitis
    • 5.1.3 Viral Conjunctivitis
  • 5.2 By Formulation Type
    • 5.2.1 Ointment
    • 5.2.2 Drops
    • 5.2.3 Drugs
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Novartis AG
    • 6.1.2 Bausch & Lomb Incorporated
    • 6.1.3 Allergan Plc
    • 6.1.4 NicOx S.A.
    • 6.1.5 Alembic Pharmaceuticals
    • 6.1.6 Sanofi S.A.
    • 6.1.7 Pfizer Inc.


Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!